DALLAS, June 17, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring biopharmaceutical stock Allos Therapeutics Inc. (Nasdaq:ALTH). The report includes the most ...

Finding companies that have all the right stuff can produce winners. Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you ...

WESTMINSTER, Colo., Apr 27, 2010 (BUSINESS WIRE) --Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the appointment of Charles Morris, MB ChB, MRCP, as ...

Spectrum PharmaceuticalsShiv Kapoor, 702-835-6300Vice President, Strategic Planning & Investor RelationsorAllos TherapeuticsMonique Greer, 720-540-5268Vice President, Corporate Communications & ...

We have recently downgraded Allos Therapeutics Inc. ( ALTH) to Neutral from Outperform with a target price of $1.50. The failure of Allos' deal with AMAG Pharma ( AMAG) in October 2011 has reverted ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Spectrum Phamaceuticals Inc. (NASDAQ: SPPI) has agreed to ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ:ALTH) today announced the Company will hold a webcast conference call on Wednesday, September 2, 2009 to discuss the outcome of ...

Mundipharma agreed to pay $310.5 million in milestones, gaining rights outside the U.S. and Canada. Allos Therapeutics could see up to $360.5 million under a collaboration with Mundipharma to ...

WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced the appointment of Charles Morris, MB ChB, MRCP, as executive vice president, chief medical officer, ...

We have recently downgraded Allos Therapeutics Inc. (NasdaqGS:ALTH - News) to Neutral from Outperform with a target price of $1.50. The merger with AMAG was announced in July 2011. The deal failed to ...